BA
The Boeing Company
BA has lower modeled downside risk, despite its lower overall score.
SRTA
Strata Critical Medical, Inc.
SRTA has the edge over BA overall, supported by stronger modeled upside.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
SRTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Stable | |
| Strong |
SRTA's revenue and balance sheet are currently healthy, and its cash flow is stable, but its profitability is under pressure.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
SRTA PE Valuation
SRTA has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 100x next year's earnings.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
SRTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SRTA to return to profit, with revenue growing.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has the edge over SRTA on earnings quality, reporting a profit while its opponent remains loss making.
SRTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.06 | — |
| Q3 2026 | -$0.29 | -158% |
| Q2 2026 | $0.50 | +$0.73 |
| Q1 2026 | $0.57 | +$0.90 |
| Q4 2025 | $0.50 | +$0.85 |
| Q3 2025 | $0.50 | +$1.19 |
| Q2 2025 | -$0.23 | +$0.43 |
| Q1 2025 | -$0.33 | +$0.35 |
| Q4 2024 | -$0.35 | +$0.41 |
SRTA has swung to a loss: it lost $0.29 per share over the past year, after a profit the year before.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA has the edge over SRTA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA has the edge over SRTA on profitability, with a higher operating margin.
SRTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $74.1M | +50% |
| Q2 2026 | $72.5M | +2.4% |
| Q1 2026 | $67.4M | +24% |
| Q4 2025 | $66.8M | +23% |
| Q3 2025 | $49.3M | -34% |
| Q2 2025 | $70.8M | +4.2% |
| Q1 2025 | $54.3M | +5.4% |
| Q4 2024 | $54.4M | +14% |
SRTA's revenue has grown year over year for four quarters in a row: $74M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.2% | +6.2 points |
| Q2 2026 | -7.5% | -0.5 points |
| Q1 2026 | -4.4% | +9.6 points |
| Q4 2025 | -9.6% | +5.8 points |
| Q3 2025 | -11% | -6.7 points |
| Q2 2025 | -7% | +11 points |
| Q1 2025 | -14% | +5.2 points |
| Q4 2024 | -15% | +60 points |
SRTA's operating margin was −5.2% last quarter, up 6.2 points from the same quarter a year ago.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over SRTA on cash flow, with more consistent year-over-year improvement.
SRTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.1M | +$49.2M |
| Q2 2026 | $3.2M | +$8.6M |
| Q1 2026 | -$1.3M | +$1.6M |
| Q4 2025 | -$10.2M | -$3.8M |
| Q3 2025 | -$40.1M | -$37.2M |
| Q2 2025 | -$5.4M | +$2.4M |
| Q1 2025 | -$2.9M | +$13.5M |
| Q4 2024 | -$6.3M | +$3M |
SRTA's free cash flow has turned positive after six years mostly in the red: $806,000 over the past year.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has the edge over SRTA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
SRTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +2.1M shares |
| 1 year | +7.1% | +5.8M shares |
| 3 years | +9% | +7.3M shares |
| 5 years | +71% | +36.7M shares |
| Available history | +977% | +80.1M shares |
SRTA has 88M diluted shares, up 7.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2019 | — |
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
SRTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -10.7x | Net Cash |
SRTA has the edge over BA on leverage, with a lower net debt burden relative to earnings.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
SRTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 49.4 | Neutral |
SRTA's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
SRTA PE vs Industrials Sector
| Metric | SRTA | Sector median | Relative |
|---|---|---|---|
| PE | 8.9x | 24x | 63% below |
| PE % | 20 | 58 | 38 pts below |
SRTA has the edge over BA on valuation relative to its sector.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
SRTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.95 | 17% above |
| 20 week MA | $5.25 | 9.9% above |
| 50 week MA | $5.11 | 13% above |
| 100 week MA | $4.53 | 27% above |
| 200 week MA | $3.94 | 46% above |
SRTA has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
SRTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.83 | $11.0 | +12% |
| 2021 | $11.0 | $9.25 | -16% |
| 2022 | $9.25 | $3.50 | -62% |
| 2023 | $3.50 | $3.53 | +0.9% |
| 2024 | $3.53 | $4.41 | +25% |
| 2025 | $4.41 | $4.87 | +10% |
| 2026 YTD | $4.87 | $5.77 | +18% |
SRTA has the edge over BA on returns for 2026, with the stronger performance.